The purpose of this study was to examine the effect of sleep quality improvement on neuropsychological symptoms and blood levels of Aβ peptides and Tau proteins in Alzheimer’s disease patients with mild–moderate cognition impairments. The gene discussed is MAPT; the disease is early-onset autosomal dominant Alzheimer disease.